The Generative Artificial Intelligence
In the service of precision medicine
Development of innovative healthcare solutions
GeodAIsics develops medical software based on its own artificial intelligence technology. Our technology, called Generative Manifold Learning (GML), enables us to create and develop tailored software solutions designed to support both patients and healthcare professionals.
Our physicians, data scientists and engineers have developed GML®, a proprietary technology that makes it possible to build sovereign medical AI applications without relying on massive training datasets.
Using targeted validation cohorts, GML® enables the rapid development of fully proprietary products capable of combining MRI data, biological data and clinical information to reveal patient-specific signatures and improve the characterisation of neurodegenerative diseases, blood disorders and cancers.
GeodAIsics is now preparing the next step: bringing these applications together within a single platform designed to speed up their development, validation and deployment.
This is our vision of personalised medicine: technology that does not replace the physician, but gives them a more complete understanding of each patient, supported by a committed, passionate and constantly growing medical, scientific and technology team.
The benefits of GML® technology
Explainability
Our software is not a black box; we explain how and why it works.
Shared foundation
Our software solutions are built on a single deterministic AI-based core.
Unsupervised
Input data labelling is not required, reducing development time and costs.
Green IT
We take an environmentally responsible approach to developing our solutions.
GeodAIsics develops software using GML® technology, based on two distinct market approaches:
The GeodAIsics Software Suite ®
GeodAIsics designs a suite of proprietary software solutions combining artificial intelligence with clinical excellence. These proprietary imaging and laboratory medicine solutions are widely distributed in France by our radiologist and laboratory medicine specialist partners, as well as by distributors located throughout Europe. BrainGML®-AD detects and monitors biomarkers associated with Alzheimer’s disease, providing clinicians with reliable quantitative indicators to improve diagnosis and therapeutic monitoring. BrainGML®-MS accurately characterises lesions associated with multiple sclerosis and objectively assesses their progression over time.
BioGML® goes even further by intelligently adapting laboratory test orders as they enter the laboratory. It facilitates patient monitoring and supports the early detection of diseases while respecting medical ethics and the budgetary constraints of healthcare institutions.
Our algorithms, trained and validated using real-world data, deliver robust results that can be used in everyday clinical practice. Designed to integrate seamlessly into existing workflows, our software saves healthcare teams valuable time while improving the accuracy of clinical decisions. Easy to use, it requires no technical expertise in artificial intelligence.
Compliant with the regulatory requirements of the healthcare sector, our solutions place the protection of patient data at the heart of their design. With GeodAIsics, technological innovation supports more precise, faster and more accessible healthcare.
Our CUSTOM SOFTWARE
GeodAIsics develops custom software based on our patented GML® technology, designed to integrate directly into laboratory analysers, middleware and other existing systems. GML® adapts to your use case, your technical constraints and your target market to create a truly custom-built software solution or software component.
A clear partnership with clearly defined roles
GeodAIsics acts as a critical supplier under CE (MDR) and FDA regulatory frameworks. Our role is to design, develop and document the technological component incorporating our GML® expertise, with the level of rigour and traceability required by these regulatory standards.
We provide our scientific expertise and regulatory compliance knowledge to secure the technological component of your project. The client remains solely responsible for placing the finished product on the market and commercialising it, whether it is a complete software solution or a component integrated into a wider device. The client is responsible for obtaining CE marking or FDA authorisation for the final product, as well as for all resulting regulatory and commercial obligations.
Why choose GeodAIsics
Sovereign and transparent technology, controlled from end to end, with no dependence on opaque foreign components — an essential guarantee of trust in the medical sector.